Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma

Mise à jour : Il y a 4 ans
Référence : NCT00076011

Femme et Homme

Extrait

The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.


Critère d'inclusion

  • Kidney Neoplasms

Liens